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Abstract 
 
Background: Genome-wide association studies have recently identified over 400 loci that harbor 
DNA sequence variation that influence blood pressure (BP). Our earlier work identified 156 single 
nucleotide variants (SNVs) with suggestive associations with BP from meta-analyses of Exome 
chip genotypes. We previously confirmed 56 of these with validation in independent consortia.  
 
Methods and Results: Here, we augment the sample with 140,886 European individuals from UK 
Biobank, in whom 77 of the remaining 100 SNVs were available for association analysis with 
systolic or diastolic blood pressure (SBP, DBP) or pulse pressure (PP). We performed two meta-
analyses, one comprised individuals of European, South Asian, African and Hispanic descent (pan-
ancestry, ~475,000), and the other included only the subset of individuals of European descent 
(~423,000).  
  
Twenty-one SNVs were genome-wide significant (P < 5x10-8) for BP, of which four are new BP 
loci: rs9678851 (missense, SLC4A1AP), rs7437940 (AFAP1), rs13303 (missense, STAB1) and 
rs1055144 (7p15.2). In addition, we identified a potentially independent novel SNV (rs3416322 
(missense, SYNPO2L) at a known locus, uncorrelated with the previously reported SNVs. Two 
SNVs are associated with expression levels of nearby genes, and SNVs at three loci are associated 
with other traits. One of the 22 SNVs with minor allele frequency < 0.01, (rs3025380 at DBH) was 
genome-wide significant. 
 
Conclusions: We report four novel loci associated with blood pressure regulation, and one 
independent variant at an established blood pressure locus. This analysis highlights several 
candidate genes with variation that alters protein function or gene expression for potential follow-
up. 
 
Key words from the journal subject terms and two additional in red color: “Blood Pressure”, 
“Genetics”, “Genetic, Association Studies”, “Gene Expression and Regulation”, “Exome chip”, 
“UK Biobank”. 
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High blood pressure (BP) is a major risk factor for coronary artery disease, heart failure,  stroke, 
renal failure and premature mortality 1. High blood pressure was estimated to cause 10.7 million 
deaths worldwide in 2015 2, 3. Pharmacologic interventional trials of BP-lowering therapies in 
patients with hypertension have demonstrated reductions in cardiovascular complications, 
including mortality 4. While several anti-hypertensive drug classes exist, variable response by 
individual patients and ethnic/racial groups, and residual risks, suggest that identification of 
previously unrecognized BP regulatory pathways could identify novel targets and pave the way 
for new treatments for cardiovascular disease prevention. 
 
Genetic association studies have identified over 400 loci at P < 5x10-8 that influence BP 
5-11. Two recent reports independently performed discovery analyses, in sample sizes of up to 
~146k (CHARGE Exome BP consortium) and ~192k individuals (the European-led Exome 
consortia [contributory consortia, CHD Exome+, ExomeBP, and GoT2D:T2DGenes]) 8, 9.  All 
samples were genotyped on the Exome chip array that was designed to interrogate rare and low 
frequency non-synonymous and other putative functional variants, as well as non-coding variants 
for association with biomedical traits. They each identified ~80 promising single nucleotide 
variant (SNV) associations with systolic blood pressure (SBP), diastolic blood pressure (DBP), 
pulse pressure (PP) or hypertension and took them forward for replication in the reciprocal 
consortium 8, 9 resulting in the identification of 56 novel BP-associated loci, including 
associations with coding and rare SNVs. A total of 100 SNVs remained of interest, but did not 
achieve genome-wide significance. By increasing the sample size, additional BP-associated 
SNVs may be identified amongst these loci.  
 
In the current report, we have augmented the sample size of these studies with up to 
140,886 European individuals from the UK Biobank, and analyzed 77 SNVs available in UK 
Biobank for association with SBP, DBP and PP, in a total sample size of up to ~475,000 
individuals (up to ~423,000 EUR).  
 
Materials and Methods 
Samples 
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These analyses consisted of a meta-analysis of results from three independent 
publications, the CHARGE Exome BP consortium8, European-led Exome consortia 
(contributory consortia, CHD Exome+, ExomeBP, and GoT2D:T2DGenes) 9 and the BP analyses 
from the UK Biobank Cardiometabolic consortium11.  
 
The CHARGE Exome BP consortium included 120,473 individuals of EUR descent from 
15 cohorts, 21,503 individuals of African (AFR) descent from 10 cohorts and 4,586 individuals 
of Hispanic (HIS) ancestry from 2 cohorts as previously described8. The European-led consortia 
included 165,276 individuals of EUR descent from 51 cohorts and 27,487 individuals of South 
Asian (SAS) descent from two cohorts 9. The UK Biobank data included 140,886 unrelated 
individuals of EUR descent11.  
 
All samples from the CHARGE and European-led Exome consortia were genotyped on 
Exome arrays that includes ~242,000 markers > 90% of which are non-synonymous or splice 
variants, with enrichment for variants with MAF < 0.05. The UK Biobank used the Affymetrix 
UK Biobank Axiom Array (N~100,00), or the Affymetrix UK BiLEVE Axiom Array 
(N~50,000) to genotype ~800,000 SNVs with subsequent imputation based on UK10K 
sequencing and 1000 Genomes reference panels. SNVs with an imputation threshold INFO score 
of < 0.10 were filtered by the Warren et al. UK Biobank Nature Genetics 2017 manuscript, from 
which the SNP association statistics for UK Biobank were provided 11. Imputation scores in the 
UK Biobank samples for the variants presented in Table 1 were with INFO > 0.6. SNVs that 
produced significant results are highlighted in green in Supplemental Tables 1 and 2, with an 
INFO median of 1. The studies by Surendran et al., Liu et al. and Warren et al. examined genomic 
inflation factors in the contributing studies and the combined meta-analyses for each of the traits 
analysed. Genomic inflation ranged between 1.04 and 1.11 in these contributing studies and 
therefore did not suggest there were significant issues with population stratification 8, 9, 11. In the 
current analyses, 77 non-validated BP-associated SNVs were available for analysis across all 
three datasets.   
 
Institutional Review Board (IRB) approval was obtained from each participating cohort 
and informed consent was obtained from all subjects 8, 9. The UK Biobank study has approval 
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from the North West Multi-Centre Research Ethics Committee and has Research Tissue Bank 
approval. 
 
Phenotypes 
Three BP traits were examined: systolic BP (SBP), diastolic BP (DBP) and pulse pressure 
(PP), where PP was calculated as the difference between SBP and DBP. For individuals taking 
anti-hypertensive therapies, 15 mm Hg and 10 mm Hg were added to the observed SBP and DBP, 
respectively, to estimate the BP that would be observed off anti-hypertensive therapy 12, 13. The 
traits were approximately normally distributed, and no transformations of the traits were 
performed. 
 
Statistical analyses 
In the CHARGE Exome BP consortium, in cohorts of unrelated individuals single SNV 
association tests were implemented via linear regression in R/PLINK/SNPTEST. For family-
based cohorts linear mixed effects models in R was used to estimate kinship via R KINSHIP2 
package and using the LMEKIN function, to account for familial correlations (https://cran.r-
project.org/web/packages/coxme/vignettes/lmekin.pdf; Supplemental Table 21 of Liu et al. 8). 
The component studies of the European-led consortia (CHD Exome+, ExomeBP and 
GoT2D:T2D genes) used linear regression as implemented in PLINK 14 or linear mixed models 
as implemented in Genome-Wide Efficient Mixed Model Association (GEMMA) 15 or EPACTS 
(the Efficient Mixed-Model Association eXpedited, EMMAX) 16, to test variants for association 
with BP traits. The UK Biobank study used linear regression models as implemented in 
SNPTEST 17. All studies assumed an additive allelic effects model. 
 
All studies adjusted for age, age2, sex, body mass index and additional cohort- specific 
covariates including (where appropriate) principal components of genetic ancestry, field centers, 
genotyping array, or case/control status for samples ascertained on case/control status for a non-
BP trait. Both study-level QC and central QC was performed prior to the meta-analyses being 
performed. Full details are given in the reports from the component consortia 8, 9, 11.  
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At the consortium level, meta-analyses of cohort-level association results were performed 
independently within CHARGE-Exome and the European-led Exome consortia using invervse 
variance-weighted fixed effects meta-analysis. These meta-analyses results were combined with 
the UK Biobank association results using fixed effects inverse variance weighted meta-analysis 
as implemented in METAL 18. Two meta-analyses were performed, one pan-ancestry (AA, EUR, 
HIS, SAS), and a second of EUR ancestry. Statistical significance was set at genome-wide 
significance, P < 5x10-8.  
 
Functional annotation 
 Associated variants were annotated using HG38 dbSNP and Entrez Gene (NCBI). We 
interrogated publically available gene expression regulatory features from ENCODE and 
ROADMAP Epigenome projects using HaploReg 19 and RegulomeDB 20. eQTLs were assessed 
using data from GTEx 21 GRASP 22, Westra et al. 23, Lappalainen et al. 24 and STARNET 25. In 
addition we used the FHS eQTL results from microarray-based gene and exon expression levels 
in whole blood from 5,257 individuals 26. We queried whether any of the five BP-associated 
SNVs were eQTLs for genes in the five BP-associated regions, or whether they were in LD (r2 > 
0.8) with any of the eQTLs for genes in these regions. Where putative eQTLs were identified, we 
verified the BP-associated SNVs were in LD (r2 >0.8) with the top eQTL for that gene.  
We interrogated publically available GWAS databases through PhenoScanner 27, a 
curated database holding publicly available results from large-scale genome-wide association 
studies facilitating “phenome scans”. We report results for SNVs with P-value  ≤ 5x10-8. 
Capture HiC interactions were accessed from the Capture HiC Plotter (www.CHiCP.org). 
Javierre et al 28 used an interaction confidence score derived using CHiCAGO software 29. The 
interactions with a CHiCAGO score ≥ 5 in at least one cell type were considered as high-
confidence interactions. 
 
Results 
Association results for the 77 SNVs with the three BP traits are shown in Supplemental 
Table 1 for the pan-ancestry (PA: European, South Asian, African and Hispanic descent) meta-
analysis and in Supplemental Table 2 for the European (EUR) meta-analysis. Twenty-two of  the 
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77 SNVs had minor allele frequency (MAF) ≤ 0.01. Twenty-one of the 77 SNVs were associated 
with at least one BP trait with genome wide significance, P < 5x10-8 and concordant directions 
of effects across the results from all contributing datasets (Table 1). Sixteen SNVs (PKN2, 
ARHGEF3, AFAP1, ANKDD1B, LOC105375508, ZFAT, RABGAP1, DBH, SYNPO2L, BDNF-
AS, AGBL2, NOX4, CEP164, HOXC4, CFDP1 and COMT) were genome-wide significant in 
both PA- and EUR samples. Two SNVs at SLC4A1AP and 7p15.2, respectively, were significant 
only in the PA sample; and three SNVs at STAB1/NT5DC2, KDM5A and LACTB only in the 
EUR sample. All the significant SNVs were common (minor allele frequencies ≥ 0.19), except 
the SNV at the DBH locus (PA, MAF = 0.0043). While this report was in preparation, 17 of these 
loci were published 7, 10, 11. Four loci remain novel: rs9678851 (SLC4A1AP, missense), rs7437940 
(AFAP1, intron), rs13303 (STAB1, missense) and rs1055144 (7p15.2, non-coding transcript; 
Supplemental Figures 1a-d). Locus SLC4A1AP was associated with SBP and AFAP1 and 7p15.2 
were associated with PP. We also observed a potentially new independent BP association (r2 ~ 
0.001 in 1000G EUR and PA samples) at a recently published locus rs34163229 (SYNPO2L, 
missense; Table 1; Supplemental Figure 1e). We used a conservative r2 < 0.1 threshold to 
minimize the possibility of an association due to hitch-hiking on a strongly associated established 
BP variant. Furthermore, conditional analyses within only the ~140,000 UK Biobank participants 
with comprehensive genomic coverage suggested that the association with SBP of rs34163229 
was independent of the established SNV, rs4746172. Regional association plots in UK Biobank 
are provided in Supplemental Figures 2a-e.  Conditional analyses within the full dataset was not 
possible given the targeted nature of the Exome array which makes claims of independence 
provisional.  
 
Three of the five newly discovered BP-associated SNVs are missense variants, mapping 
to SLC4A1AP, STAB1 and SYNPO2L (Table 1 and Supplemental Table 3). At SLC4A1AP, 
rs9678851 (C>A,  Pro139Thr) has MAF=0.46 and the C allele is associated with an increase of 
0.23 mmHg in SBP. This variant is correlated with two other missense variants in C2orf16 
(rs1919126 and rs1919125, r2 = 0.81 (EUR) based on 1000G 30, for both). At STAB1, the C allele 
of rs13303 (T>C, Met2506Thr, with MAF=0.44) is associated with an increase of 0.15 mmHg 
in PP per minor allele in EUR. This residue is located in a conserved region of the protein 31 
(Supplemental Table 4). The T allele of rs34163229, the new association at the SYNPO2L locus, 
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(G>T, Ser833Tyr, with MAF=0.15), is associated with an increase of 0.36 mmHg in SBP per 
allele. This variant is in LD with another missense variant in SYNPO2L (rs3812629 r2=1, 1000G 
EUR) 30. Using Polyphen2 (http://genetics.bwh.harvard.edu/pph2/index.shtml), the SNVs 
rs9678851 of SLC4A1AP, and rs13303 of STAB1 were predicted to be benign, while rs34163229 
of SYNPO2L was predicted to have a possible damaging impact on the corresponding human 
proteins’ structure and function. 
 
We interrogated publicly available expression quantitative trait loci (eQTL) datasets 
through GTEx, ENCODE, RoadMap projects, PhenoScanner 27, STARNET 25 and Framingham 
Heart Study generation 3 26 to further highlight potential causal genes and mechanisms at the 
newly identified BP loci (Supplemental Table 3). The PP-associated SNV, rs13303, at STAB1 is 
correlated (r2 >0.8 1000G EUR) with the top eQTLs for NT5DC2 in atherosclerotic-lesion free 
internal mammary artery, atherosclerotic aortic root, subcutaneous adipose, visceral abdominal 
fat and liver tissues (all P < 1x10-11) 25. The rs13303 was also associated with expression levels 
of NT5DC2 in EBV-transformed lymphocytes, transformed fibroblasts 25 and thyroid cells 
(Supplemental Table 3) 21. The SBP-associated SNV at SYNPO2L (rs34163229) is correlated 
(r2=0.86 in 1000G EUR) with the top eQTL (rs2177843) for MYOZ1 in heart atrial appendage 
tissue (Supplemental Table 3) 21. The five new BP associated SNVs were not in LD with the top 
eQTLs for these gene regions in whole blood in the Framingham Heart Study eQTL data. We 
also took the opportunity to assess whether the additional fifteen recently established genome-
wide significant BP-associated SNVs were eQTLs in the FHS sample. Amongst the genome-
wide significant BP SNVs, three, rs4680 at COMT, rs12680655 at ZFAT and rs10760260 at 
RABGAP1, were the top eQTL for the corresponding genes in whole blood  (Supplemental Table 
5). We also examined the five BP-associated SNVs in endothelial precursor cell Hi-C data 
[www.chicp.org; 28, 32] to explore long-range chromatin interactions. rs13303 was found to 
contact NISCH (score 17.34) and rs34163229 contacts USP54 (score 33.89)  
 
 Finally, we assessed the association of the new BP-associated variants and their close 
proxies (r2>0.8) with cardiovascular disease risk factors, molecular metabolic traits and clinical 
phenotypes using PhenoScanner, the NHGRI-EBI GWAS catalog and GRASP 27. We observed 
five of the newly discovered BP-associated SNVs to have genome wide significant associations 
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with other traits, including height (7p15.2) 33, waist-to-hip ratio (STAB1 and 7p15.2) 34, 35, 
triglycerides (SLC4A1P), adiponectin levels (STAB1) 36 and our rs34163229 of SYNPO2L is in 
high LD with rs7915134, D’=0.99 and R2=0.92 in the EUR 1000G samples. Rs7915134 is 
found recently to be associated with atrial fibrillation 37 (Supplemental Table 3).  
Of the 77 analysed SNVs, which were selected as lookups in the original Exome analyses, 
56 SNVs were not genome-wide significant in the current analysis. With ~300 BP loci reported 
since the time of our analysis, we tested whether any of the 56 SNVs that were not genome-
wide significant in our meta-analysis have been reported as new BP-associated loci in any of 
the three recent publications 7, 10, 11. Twelve SNVs in our dataset were located within 1 Mb of a 
recently reported BP locus : CACNA1S, TSC22D2, RPL26L1, EDN1, GPRC6A, ACHE, CAV1, 
NOX5, PGLYRP2, NAPB, EDEM2 and KCNB1; (Supplemental Tables 1 and 2), although none 
of the SNVs were in LD (r2 >0.1 in all 1000G populations) with the published variants at these 
loci. 
 
Discussion 
We identified genome-wide significant associations with BP for 21 additional SNVs from 
our original Exome Chip analyses 8, 9 by including UK Biobank participants to augment our 
sample size to ~475,000 individuals. Four of the twenty-one loci were novel, of which two were 
missense variants, and one was a putative new independent signal at an established locus and 
was a missense variant.  
A missense SNV in SLC4A1AP, rs9678851 marks the PP-associated locus on 
chromosome 2. SLC4A1AP, encodes a solute carrier also known as kidney anion exchanger 
adapter protein, although it is widely expressed in most GTEx tissues.  
  
 At the new locus on chromosome 3 (rs13303), three potential candidate genes are 
highlighted: STAB1, NT5DC2 and NISCH. STAB1 encodes stabilin1, a protein known to 
endocytose low density lipoprotein cholesterol, gram-positive and -negative bacteria, and 
advanced glycosylation end products 38, 39. The gene product is also referred to as CLEVER-1, 
a common lymphatic endothelial and vascular endothelial receptor-1 40, which is expressed in 
macrophages 41. SNX17 interacts with STAB1 and is identified as a trafficking adaptor of 
STAB1 in endothelial cells 38, 42. The rs13303 is located 500bp downstream of NT5DC2. This 
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additional gene is highlighted through the association of rs13303 with expression of NT5DC2 
in multiple tissues (Supplemental Table 3). NT5DC2 encodes the 5'-nucleotidase domain 
containing 2 protein. The gene is widely expressed, with higher levels observed in the heart and 
coronary artery, although its function is unknown. Lastly, exploration of long-range chromatin 
interaction identified contact of the SNV region with the genetic sequence including the gene 
NISCH, which encodes the nonadrenergic imidazoline-1 receptor protein localized to the 
cytosol and anchored to the inner layer of the plasma membrane. This protein binds to the 
adapter insulin receptor substrate 4 (IRS4) to mediate translocation of alpha-5 integrin from the 
cell membrane to endosomes. In human cardiac tissue, this protein has been found to affect cell 
growth and death 43.  
 
The PP-associated variant, rs7437940 on chromosome 4 is intronic to AFAP1, and is 
located in promoter histone marks in right atrial tissue, based on regulatory chromatin states 
from DNAse and histone ChIP-Seq in Roadmap Epigenomics Consortium (identified with 
HaploReg, Supplemental Table 4) 44. AFAP1 encodes actin filament associated protein 1. This 
protein is thought to have a role in the regulation of actin filament integrity, and formation and 
maintenance of the actin network 45.  
 
At the locus on chromosome 10 (rs34163229), two candidate genes were highlighted 
(SYNPO2L and MYOZ1). SYNPO2L encodes synaptopodin like 2, which is not well 
characterized, but may play a role in modulating actin-based shape. The lead SNV is also 
associated with expression levels of MYOZ1 in heart appendage tissues. MYOZ1 encodes 
myozenin 1, an alpha actinin and gamma filamin binding Z line protein predominantly 
expressed in skeletal muscle 46.  
 
At two loci (SLC4A1AP and SYNPO2L) we observed more than one missense variant in 
high LD (r2 > 0.8). Functional follow up of these variants may be challenging to disentangle the 
causal variants. At the SLC4A1AP locus, there are three misssense variants, none of which are 
predicted to be damaging. Two of these are in C2ORF16, which is predicted to encode an 
uncharacterized protein. The evidence at the moment is at the transcriptional level. Cellular 
assays comparing the function of SLC4A1AP with the missense variant may be developed or an 
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animal model could be created and BP can be measured. In the first instance, a knockout model 
may be required, due to the predicted weak effects of the BP variants. At the SYNPO2L locus, 
the two missense variants are both in SYNPO2L, of which one is predicted damaging, cellular 
experiments testing functional effecs of this variant alone or part of a haplotype maybe a good 
starting point.  
 
In conclusion, we identify four new loci and one potential new SNV in a known locus, 
that influence BP variation and highlight specific genes and pathways that could potentially 
facilitate an improved understanding of BP regulation, and identify novel therapeutic targets to 
reduce the burden of cardiovascular disease. 
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Table 1. Variants associated with SBP, DBP or PP in the Pan-ancestry or EUR-ancestry meta-analyses in up to ~475,000 individuals.  
rsID Gene Annotation chr-pos Trait Meta a1/2 Freq1 b(S.E.) P-value Dir HetP N UK-
BioBank 
INFO 
New loci              
rs9678851 SLC4A1AP missense 2-27664167 S PA a/c 0.54 -0.23 (0.04) 1.07E-09 --- 0.09 474,569 1.0000 
rs13303* STAB1 missense 3-52523992 P EUR t/c 0.44 -0.15 (0.03) 3.72E-08 --- 0.11 418,405 1.0000 
rs7437940 AFAP1 Intronic 4-7885773 P EUR,PA t/c 0.47 -0.15 (0.03) 2.88E-08 --- 0.007 420,616 0.9974 
rs1055144 7p15.2 nc-transcript 7-25831489 P PA a/g 0.19 0.19 (0.03) 3.47E-08 +++ 0.18 453,880 1.0000 
Recently reported loci             
rs786906 PKN2 synonymous 1-88805891 S,P EUR,PA t/c 0.44 0.19(0.03) 1.29E-12 +++ 0.08 422,556 1.0000 
rs3772219 ARHGEF3 missense 3-56737223 S,D EUR,PA a/c 0.68 0.25(0.04) 2.00E-10 +++ 0.25 474,558 1.0000 
rs40060 ANKDD1B 3'UTR 5-75671561 D EUR,PA t/c 0.65 -0.17(0.02) 3.47E-12 --- 0.46 422,598 0.9938 
rs972283 LOC105375508 intronic 7-130782095 S,D EUR,PA a/g 0.47 -0.23(0.04) 9.12E-10 --- 0.1 474,569 1.0000 
rs12680655 ZFAT intronic 8-134625094 S,D EUR,PA c/g 0.6 -0.29(0.04) 1.62E-12 --- 0.18 402,962 1.0000 
rs10760260 RABGAP1 intronic 9-122951247 P EUR,PA t/g 0.14 -0.25(0.04) 2.88E-10 --- 0.12 421,223 0.9975 
rs3025380 DBH missense 9-133636634 S,D EUR,PA c/g 0.004 -1.14(0.19) 1.23E-09 --- 0.05 400,891 0.8763 
rs34163229* SYNPO2L missense 10-73647154 S,P EUR,PA t/g 0.15 0.36(0.05) 1.15E-11 +++ 0.32 448,759 1.0000 
rs925946 BDNF-AS intronic 11-27645655 D EUR,PA t/g 0.31 -0.16(0.02) 7.08E-12 --- 0.25 474,564 1.0000 
rs12286721 AGBL2 missense 11-47679976 S,D EUR,PA a/c 0.56 -0.17(0.02) 3.39E-13 --- 0.05 422,593 1.0000 
rs10765211 NOX4 intronic 11-89495257 P EUR,PA a/g 0.38 -0.19(0.03) 6.46E-12 --- 0.05 474,550 0.9964 
rs8258 CEP164 3'UTR 11-117412960 P EUR,PA a/g 0.37 0.22(0.03) 1.95E-15 +++ 0.003 422,546 1.0000 
rs11062385 KDM5A missense 12-318409 P EUR a/g 0.73 -0.17(0.03) 2.69E-08 --- 0.84 422,563 1.0000 
rs7136889† HOXC4 intronic 12-54043968 S,P EUR,PA t/g 0.69 0.36(0.05) 1.58E-13 +++ 0.33 419,905 0.6070 
rs2729835* LACTB missense 15-63141567 S EUR a/g 0.68 -0.24(0.04) 1.29E-08 --- 0.25 394,656 1.0000 
rs2865531 CFDP1 intronic 16-75356418 S,P EUR,PA a/t 0.6 0.42(0.06) 2.14E-13 +++ 0.51 217,419 0.9998 
rs4680 COMT missense 22-19963748 P EUR,PA a/g 0.51 0.16(0.03) 2.24E-09 +++ 0.005 418,385 1.0000 
 
Note: rsID-SNV name, Gene-name of the closest gene or cytogenetic band based on Gene Entrez of NCBI; Annotation-SNV 
annotation based on dbSNP of NCBI; Chr-pos-chromosome-bp position in Human Genome build 38; Trait- the blood pressure trait 
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(DBP, SBP or PP) the variant is associated with; Meta- the meta-analysis the variant is associated in, Pan-Ancestry and/or EURopean; 
A1/2-allele 1/allele 2; Freq1-allele frequency for allele 1;  (SE)-effect estimate,  and its standard error for allele 1 from the 
corresponding meta-analysis (highlighted in bold); P-value – P from meta-analysis (highlighted in bold); Direction- direction of effect 
in each of the contributing consortia in the following order: EUROPEAN led Exome Consortia, UK-BIOBANK and CHARGE-BP 
Consortium; HetP- P-value of heterogeneity across the three contributing consortia, N- Sample size for the trait and meta-analysis 
with the lowest P-value (bold). * indicates potential new signal at a recently reported locus (LD- r2 < 0.1 with a published BP SNV), 
and † indicates first report of this variant as genome-wide significant. For more details, see Supplemental Tables 1 and 2. UK-
BIOBANK INFO- a quality of imputation score in UK BIOBANK. Imputation scores in the UK Biobank samples for the variants 
presented in Table 1 had an INFO > 0.6. 
 
